Quintiles, Quest Diagnostics in clinical trials JV; Cerulean raising $50M;

@FierceBiotech: Skincare startup bags $50M to get its acne drug into Phase III. Article | Follow @FierceBiotech

@JohnCFierce: Merck ties up with tiny Syndax on a 'breakthrough' cancer combo. News | Follow @JohnCFierce

@DamianFierce: This could be the lingering effects of watching Going Clear, but doesn't Jadenu sound like an evil space lord? Novartis' release | Follow @DamianFierce

> Quintiles ($Q) and Quest Diagnostics ($DGX) are pooling their clinical trials laboratory operations into a new joint venture. Together they would have brought in $575 million last year, says Quintiles. Release

> Cerulean Pharma ($CERU) is selling $50 million in shares. Release

Medical Device News

@FierceMedDev: Medical device cybersecurity expert says better 'cybersecurity hygiene' needed. Article | Follow @FierceMedDev

@StacyALawrence: ICYMI: Philips brings in former Hologic CEO to head imaging biz in ongoing HealthTech revamp. Article | Follow @StacyALawrence

@VarunSaxena2: Japanese researchers study carbon nanotubes with drug delivery applications. FierceDrugDelivery story | Follow @VarunSaxena2

@EmilyWFierce: $PHG sold its lighting business for $2.8B. Bloomberg article | Follow @EmilyWFierce

> VA starts trial of mobile app to help manage PTSD symptoms. Story

> Philips sells LED, automotive lighting for almost $3B, readies to reinvest in HealthTech. Article

> Olympus settles accounting scandal as it struggles to address duodenoscope difficulties. Report

Pharma News

@FiercePharma: ICYMI earlier: $GSK finally seals U.K. Bexsero deal for £20 per dose. FierceVaccines story | Follow @FiercePharma

@EricPFierce: ICYMI last week from FiercePharmaManufacturing: IPCA says FDA bans will have little sales impact. Didn't Wockhardt make that claim before its profits sank? More | Follow @EricPFierce

@CarlyHFierce: New fantasy: An Invokana/Vimizim final. Tell me that doesn't sound like a Halloween dream come true. Make it happen, people. | Follow @CarlyHFierce

> Watch out, Pomalyst: Amgen gets quick FDA review for lucrative new Kyprolis use. Story

> Judge tosses Abilify kickback claims, but puts BMS on notice for firing whistleblowers. Article

> Abbott puts one-third of its $6B Mylan stake on the block. Report

Drug Delivery News

> Genisphere boasts preclinical success of 3DNA platform for cataract complications. Report

> Columbia Labs picks up multidrug intravaginal ring created at MIT and MGH. More

> Researchers convert microbubbles to even smaller nanobubbles using ultrasound. Item

> Japanese researchers studying carbon nanotubes with drug delivery applications. Story

> Novan receives $50M in support of drug delivery tech to treat acne, HPV. Article

Pharma Manufacturing News

> Mylan recalling two injectable drugs made in India. Report

> Federal authorities raid Internet pharmacy operator CanadaDrugs.com. More

> Fujifilm expands in U.S. again with deal for stem cell producer. Story

> Roche's Genentech investing $125M in Oregon plant. News

> Sanofi vaccine plant in Canada again producing ImmuCyst bladder drug. Article

Pharma Asia News

> Japan pharma market on track for $80B mark by 2020, but obstacles seen. News

> Indian company says compulsory license use has cost country $10B in potential investments. Report

> China puts stem-cell clinical trial regulation in play with draft for comment. More

> 'Japanese NIH' launches April 1 with focus on devices and drugs. Story

> Chi-Med's fruquintinib meets metastatic colorectal cancer Phase II primary endpoint. Article

 

Suggested Articles

Charles River Labs is stumping up $380 million in cash to buy out cell therapy biomaterials producer HemaCare.

Novartis’ fevipiprant has failed another pair of phase 3 clinical trials, prompting the Swiss pharma to halt further development in asthma.

All 12 members of an FDA advisory committee voted to recommend the approval of teprotumumab for a rare, autoimmune eye disease.